1 UNITED STATES DISTRICT COURT 2 NORTHERN DISTRICT OF CALIFORNIA 3 CASE NO. C04-2123 MJJ THERASENSE, INC., and ABBOTT 4 CASE NO. C04-3327 MJJ LABORATORIES. CASE NO. C04-3732 MJJ 5 AMENDED JOINT PROPOSED CASE 6 Plaintiffs, MANAGEMENT STATEMENT AND 7 VS. PROPOSED ORDER RELATING TO REMAINING CLAIM CONSTRUCTION 8 BECTON, DICKINSON AND CO., PROCEEDINGS FOR '551 AND '745 PATENTS IN SUIT AND CASE SCHEDULE 9 Defendant. **UP TO STATUS CONFERENCE** 10 AND RELATED CASES 11 12 AMENDED JOINT PROPOSED CASE MANAGEMENT STATEMENT AND 13 PROPOSED ORDER RELATING TO REMAINING CLAIM CONSTRUCTION PROCEEDINGS FOR '551 AND '745 PATENTS IN SUIT AND 14 CASE SCHEDULE UP TO STATUS CONFERENCE 15 Pursuant to the Court's Order setting a Case Management Conference for August 16 31, 2006, Plaintiffs Abbott Diabetes Care Inc., formerly known as TheraSense, Inc., and Abbott 17 Laboratories, and Defendants Becton, Dickinson & Company and Nova Biomedical Corporation 18 submit this Case Management Statement and Proposed Order relating to the remainder of the 19 20 claim construction proceedings to be completed on the two patents that will be the subject of the 21 next Markman hearing and the case scheduled up to the status conference. 22 **Description of the Cases** 23 These cases involve U.S. Patent Nos. 6,143,164, 5,820,551, 6,592,745, and 24 5,628,890 (the "Abbott patents"). The products at issue are blood-glucose test strips used for 25 diabetes care, marketed by Becton, Dickinson and Co. ("BD") and manufactured by Nova 26 Biomedical Corporation ("Nova"). Abbott Diabetes Care Inc., formerly known as TheraSense, 27 28

Inc., ("ADC") and Abbott Laboratories ("Abbott Labs") (collectively "Abbott") allege that both BD and Nova willfully infringe the Abbott patents, entitling Abbott to damages and injunctive relief. The Defendants allege that they do not infringe the Abbott patents and that the Abbott patents are invalid, thereby entitling Defendants to declaratory judgments of non-infringement and patent invalidity.

The Court conducted a claim construction hearing on the claims of the '164 Patent and the '890 Patent on July 19, 2006, for the Cases listed above (the "BD/Nova Cases"). The '551 Patent and the '745 Patent are also the subject of a patent infringement suit currently pending before this Court in Case No. C05-03117 MJJ (the "Roche/Bayer Case"). The '551 Patent and the '745 Patent for both the BD/Nova Cases and the Roche/Bayer Case will be construed at a single claim construction hearing, which will be held on January 18, 2007, at 9:00 a.m. This Case Management Statement relates only to the remaining claim construction proceedings for the '551 Patent and the '745 Patent in the BD/Nova Cases (as the parties to the BD/Nova Cases have previously exchanged most of the claim construction submissions for these patents) and the case schedule up to the status conference.

Proposed Schedule for Remainder of Claim Construction Proceedings for the '551 and the '745 Patents In Suit and Case Schedule up to Status Conference (asterisks indicate dates under Northern District Patent Local Rules)

Date	Event
December 1, 2006	Deadline for parties to file opening briefs on claim construction
December 20, 2006	Deadline for parties to file responsive briefs on claim construction
January 17, 2007, at 10:00 a.m.	Claim construction pre-hearing conference and tutorial (combined - BD/Nova and Roche/Bayer)
January 18, 2007, at 9:00 a.m.	Claim construction hearing (combined -

Cascasco 8:04-0242333 M/JJV H.Doctoon enter 11:061 Ffiled 1099/0173 2000 6 Page 23 gent 4 of 5

1		BD/Nova and Roche/Bayer)
2	February 20, 2007, at 2:00 p.m.	Status Conference
3		
4		
5	DATED September <u>Q</u> , 2006	BAKER BOTTS, LLP
6		
7		By: Strellon
8		JAMES W. CANNON, JR. (pro hac vice)
9		MUNGER, TOLLES & OLSON LLP
10 11		ROHIT K. SINGLA JASON RANTANEN
12		Attorneys for Plaintiffs
13		ABBOTT DIABETES CARE INC. and ABBOTT LABORATORIES
14		
15	DATED September (), 2006	ROPES & GRAY LLP
16	<u> </u>	
17 18		By: Dadford Bode (8 BRADFORD J. BADKE (pro hac vice)
19		MARK D. ROWLAND
20		SONA DE
21		Attorneys for Defendants
22		BECTON, DICKINSON AND COMPANY and NOVA BIOMEDICAL CORPORATION
23		
24		
25		
26		
27		
28		
		AMENDED JOINT CASE MANAGEMENT

Casease03:04-02123332/7JJVHADoctomente2nt061 Ffileadl0099/073/20006PagFeagen54of 5 **CASE MANAGEMENT ORDER** The Case Management Statement and Proposed Order Relating Solely to Remaining Claim Construction Proceedings for '551 and '745 Patents in Suit is hereby adopted by the Court and the parties are ordered to comply with this Order. 9/12/2006 Dated: UNITED STATES DISTRICT JUDGE